SynthesisFrontiers in psychiatry2026
The application of esketamine in cancer-related depressive states: attention from mechanisms to clinical translation.
Synthesis in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This article reviews the clinical status and treatment challenges of cancer-related depressive states, clarifies the mechanism of action of esketamine-a novel rapid-acting antidepressant-compares its efficacy with traditional drugs, evaluates safety and tolerability, and summarizes clinical evidence to support clinical practice and research. Methods: By searching databases such as PubMed, Web of Science, and Cochrane Library, We conducted a structured review of the available literature on the mechanism of esketamine in the treatment of cancer-related depressive states in recent years, including mechanism studies, clinical trials, and review articles. We focused on its regulation of NMDA receptors, the impact on BDNF expression, synaptic plasticity, and neural circuit remodeling, and compared its efficacy and safety with traditional antidepressants. Results: Esketamine exerts rapid antidepressant effects via multiple mechanisms: NMDA receptor antagonism, downstream signaling modulation, BDNF upregulation, synaptic plasticity enhancement, and neural circuit remodeling. Available studies suggest that esketamine may provide rapid antidepressant effects in oncology populations, particularly in perioperative settings. Common adverse events-such as transient dissociation and elevated blood pressure-are generally controllable. Conclusions: Esketamine, as a rapidly acting antidepressant, has a plausible mechanistic rationale and potential clinical value in the treatment of cancer-related depressive states. However, its long-term safety, optimal dosing regimens, and individualized application in different cancer patients still require further investigation. In the future, the integration of multi-omics technologies and clinical translational research should be promoted to advance the precision and standardization of its application in cancer-related depressive states treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.